Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Breast Neoplasms 7Esophageal Neoplasms 1Endometrial Adenocarcinoma 1Carcinoma, Intraductal, Noninfiltrating 1Breast Neoplasms, Male 1Bladder Urothelial Carcinoma 1Adenocarcinoma Of Esophagus 1

Interventions

Trastuzumab 25Paclitaxel 22Cyclophosphamide 20Docetaxel 17Taxes 14Lapatinib 13Doxorubicin 13Radiotherapy 12Bevacizumab 11Capecitabine 10Tamoxifen 9Immunohistochemistry 9sargramostim 8Granulocyte-Macrophage Colony-Stimulating Factor 8Filgrastim 8Carboplatin 8Vorinostat 6Magnetic Resonance Spectroscopy 6Erlotinib Hydrochloride 6Chemotherapy, Adjuvant 6Biopsy 6Peripheral Blood Stem Cell Transplantation 5Everolimus 5liposomal doxorubicin 4ixabepilone 4Vinorelbine 4Neoadjuvant Therapy 4Immunoenzyme Techniques 4Gene Expression Profiling 4Fluorodeoxyglucose F18 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Breast Neoplasms, Male × Ogivri × Clear all
NCT00770809 2025-08-15

Paclitaxel and Trastuzumab With or Without Lapatinib in Treating Patients With Stage II or Stage III Breast Cancer That Can Be Removed by Surgery

National Cancer Institute (NCI)

Phase 3 Completed
305 enrolled 10 charts
Breast

Breast Neoplasms, Breast Neoplasms, Male

Data powered by HemOnc (CC BY 4.0) Colophon âš¡